ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma

Cheng, Qian; Tan, Jingwen; Liu, Rui; Kang, Liqing; Zhang, Yi; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Xu, Nan; Li, Minghao; Yu, Lei*; Li, Xin*new
CYTOTHERAPY2022-10DOI: 10.1016/j.jcyt.2022.05.001
9被引5阅读
引用收藏
分享

摘要

Background aims: The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated antigens is a promising strategy that has exhibited encouraging results in clinical trials. However, few studies have focused on the effectiveness and safety of CD20 CAR T cells in rituximab-refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (B-NHL) patients, particularly those treated with rituximab for a short time. This prospective study aimed to assess the effectiveness and toxicity of CD20 CAR T cells in R/R B-NHL patients previously treated with rituximab. @@@ Methods: The authors conducted a prospective, single-center phase I study on the effectiveness and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients (no. ChiCTR2000036350). A total of 15 patients with R/R B-NHL were enrolled between November 21, 2017, and December 1, 2021. @@@ Results: An overall response rate of 100% was shown in enrolled patients, with 12 (80%) achieving complete remission and three (20%) achieving partial remission for the best response. The median follow-up time was 12.4 months. Progression-free survival and overall survival were not yet reached by the data cutoff day. No patient developed grade 4 cytokine release syndrome, and only one patient had immune effector cell-associated neurotoxicity syndrome. @@@ Conclusions: All enrolled B-NHL patients who were previously R/R to rituximab achieved different degrees of clinical response with tolerable toxicities. Notably, patients who had received rituximab within 3 months had a poorer prognosis.

学科与关键词

关键词
CAR T-cell therapyNon-Hodgkin lymphomaCD20RituximabCytokine release syndrome (CRS)
相关
加载中…
  • Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
    Qu, Changju*; Zou, Rui; Wang, Peng; Zhu, Qian; Kang, Liqing; Ping, Nana; Xia, Fan; Liu, Hailing; Kong, Danqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*Frontiers in Immunology, 2022, 13: 969660.被引 8
  • Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma
    Zhang, Ying; Geng, Hongzhi; Zeng, Liangyu; Li, Jiaqi; Yang, Qin; Jia, Sixun; Zong, Xiangping; Cai, Wenzhi; Liu, Shuangzhu; Lu, Yutong; Yu, Lei; Li, Caixia*; Wu, Depei*Hematological Oncology, 2023.
  • CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma
    Liu, Rui; Cheng, Qian; Kang, Liqing; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Zhang, Yi; Chu, Ling; Chen, Xin; Zhang, Chang; Tan, Jingwen; Xu, Nan; Li, Minghao; Yu, Lei; Li, Xin*Human Gene Therapy, 2022, 33(5-6): 318-329.被引 9
查看全部 →

发表信息

论文状态
公开发表
期刊
CYTOTHERAPY
发表日期
2022-10
卷期
第 24 卷, 第 10 期
页码
1026-1034
DOI
10.1016/j.jcyt.2022.05.001
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81870165, 82170204]; Natural Science Foundation of Hunan Province [2021JJ40916]; Third Xiangya Hospital of Central South University

作者

  • C

    Cheng, Qian (第一作者)

  • T

    Tan, Jingwen

    new

查看全部 13 位作者收起作者
  • L

    Liu, Rui

  • K

    Kang, Liqing

  • Z

    Zhang, Yi

  • W

    Wang, Erhua

  • L

    Li, Ying

  • Z

    Zhang, Jian

  • X

    Xiao, Han

  • X

    Xu, Nan

    new

  • L

    Li, Minghao

    new

  • Y

    Yu, Lei (通讯)

    new

  • L

    Li, Xin (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417